Background-Anemia in heart failure (HF) is commonly diagnosed according to hemoglobin concentration [Hb] 
O ne of the clinical characteristics of untreated heart failure (HF) is fluid accumulation leading to hemodynamic and eventually symptomatic clinical congestion. 1 Fluid retention in HF is primarily orchestrated by the activation of baroreceptors, sympathetic nervous system, renin-angiotensin-aldosterone system, and vasopressin axes. 1, 2 Fluid retention is interpreted as a compensatory response aiming to retrieve normal cardiac reserve by means of increasing blood volume (BV), venous return, and thereby stroke volume via the Frank-Starling mechanism, provided that cardiac pumping capacity remains operative. 2 Given the continuous interaction between extracellular fluid compartments, volume expansion affects both intravascular and interstitial constituents. Indeed, interstitial fluid volume may reach >30 L or 450 mL/kg body weight in untreated patients with HF, nearly tripling average values in healthy individuals. 3 The massive overload of interstitial fluid volume results in generalized edema and widespread complications, such as dyspnea, ischemia, increased risk of infection, and skin ulcers, among others. 4 Likewise, BV may exceed 100 mL/kg in patients with HF, a ≈1.5-fold increase compared with healthy controls. 5 Although BV expansion contributes to a lesser degree to overall body fluid retention, it represents a fundamental challenge for accurate diagnosis and management of anemia in patients with HF.
See Clinical Perspective
Anemia occurs when the number of red blood cells, and thus oxygen carrying capacity, barely suffices to meet metabolic demands and is conventionally defined by hemoglobin concentration ([Hb])<12.0 g/dl and <13.0 g/dl in adult females and males, respectively. 6 More than one third of patients with HF present with anemia, which is independently associated with increased risk of mortality irrespective of HF phenotype according to a large cohort comprising >150 000 individuals with HF. 7 Importantly, although [Hb] is typically used to diagnose anemia, low [Hb] , on a physiological basis, can be the result of either hemodilution due to plasma volume (PV) expansion or a genuine red blood cell deficit as reflected by reduced total red blood cell volume (RBCV). True Anemia in Heart Failure may be present with apparently variable predominance in patients with HF diagnosed with anemia conforming to low [Hb] . 8, 9 Determinants and treatment of anemia may, thus, differ according to the underlying pathophysiology as illustrated by the fact that only HF patients with true anemia may respond favorably, in terms of [Hb] correction, to erythropoietin therapy. 10 Parenthetically, a recent clinical trial in patients with moderately anemic HF could not confirm the extensive benefits associated with erythropoietin treatment suggested by previous meta-analytic evidence, 11, 12 and erythropoiesisstimulating agents have currently no indication in HF. 13 In addition, intravascular volumes and therefore [Hb] in HF may be further compounded by the prescription of drugs affecting fluid homeostasis. In this regard, long-term standard HF pharmacotherapy including β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists and in particular diuretics may result in lower PV, whereas [Hb] and hematocrit are unaltered, in patients with HF compared with healthy agematched and body weight-matched individuals. [13] [14] [15] Hence, in these patients RBCV could be reduced and dissociated from (and thereby undetected by) [Hb] measurements.
Considered collectively, true anemia (ie, reduced RBCV) in HF might be (1) masked in patients presenting with normal [Hb] and (2) determined by factors other than those associated with [Hb] . These hypotheses are, however, unclear based on the surfeit of literature assessing intravascular volumes in patients with HF. 3, 5, 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] It is possible that the small sample size, distinct HF phenotypes, and incomplete report of intravascular volumes according to established norms 27, 28 in some individual studies may have contributed to some uncertainty about the scope and determinants of true anemia in HF. A systematic review may help to obtain a comprehensive perspective and clarify the above issues, but to our knowledge, this has not yet been performed. Therefore, the primary aim of this study was to perform a systematic review of available studies determining intravascular volumes in individuals with HF. We selected studies that presented intravascular volumes normalized by ideal body weight (IBW) norms according to the International Council for Standardization in Hematology or reported anthropometrical variables required to determine intravascular volume deviation from IBW.
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Methods
Data Sources and Searches
Our systematic search included MEDLINE, Scopus, and Web of Science since their inceptions until April 2016. We used combinations of the subject headings "heart failure," "total," "red cell volume," "plasma volume," and "blood volume"; the search strategy for MEDLINE is shown in Figure I in the Data Supplement. We also performed hand searching in identified reviews, articles included in systematic review, related citations in MEDLINE and Google.
Article Selection
To be included in the systematic review, an original research article had to assess total RBCV, PV, or BV in patients with HF (1) according to International Council for Standardization in Hematology guidelines or (2) report anthropometrical variables required to determine intravascular volume deviation from IBW norms. 27, 28 In the event of multiple publications pertaining to the same research, the most comprehensive report was included. The selection of articles was not limited by language or publication status.
Data Extraction
The following variables were extracted into a preformatted spreadsheet: authors, year of publication, clinical characteristics of study participants (n, age, sex, height, weight, body mass index [BMI] , left ventricular ejection fraction [LVEF] , [Hb] , hematocrit, iron status, HF phenotype, comorbidities, and medication), intravascular volumes (RBCV, PV, and BV), and characteristics of their assessment (technique and procedure). Intravascular volume data in decompensated patients with HF at hospital admission were not used for analysis.
Data Synthesis and Analysis
RBCV, PV, and BV are presented as percentage excess or deficit of normal expected volumes. 27, 28 Normal reference intravascular volumes were determined in relation to deviations from IBW derived from Metropolitan Life tables (>100,000 measurements) adjusted for sex, body weight, and height. 24, 27 This method has been recommended for the quantitative assessment of total intravascular volumes by the International Council for Standardization in Hematology for its precision and reproducibility, and it has been validated against the gold standard double-labeled technique of chromium-tagged red cells and albumin 1 to 125 with the volumes being within 1% of one another. 29 When IBW was not explicitly reported in a given article, IBW was calculated according to BMI=22 kg/m 2 , which is associated with lowest morbidity irrespective of sex. 30 If hematocrit values were not reported, these were determined from reference guidelines for female and male Caucasian adults. 31 Metaregression analyses were performed to estimate associations between intravascular volumes and clinical variables (age, sex, weight, BMI, LVEF, [Hb], iron concentration, and ferritin concentration), taking into account the sample size and variability of intravascular volume assessment (Comprehensive Meta-analysis, Biostat, Englewood, CO). Intravascular volumes were considered as dependent variables. In all metaregression models, studies were weighted by the inverse variance of the dependent variable. A 2-tailed P value <0.05 was considered significant.
Results
Study Selection and Characteristics
The flow diagram of the process of article selection is shown in Figure 1 , which resulted in the inclusion of 14 articles. Three of these articles presented separate study groups (hence forward referred as studies), 10, 16, 25 each of which was evaluated as an individual study. Table 1 shows the main characteristics of the resulting 18 studies, encompassing a total of 368 HF patients with mean age ranging from 49 to 80 years. Seven studies were comprised patients with heart failure with reduced ejection fraction (HFrEF; n=210), 6 studies comprised patients with heart failure with preserved ejection fraction (HFpEF; n=99), 1 study involved HFrEF (n=13) and patients with HFpEF (n=4), and 4 studies did not distinguish between HF phenotypes (n=42). Five studies were comprised men (n=56) and the remaining studies included men (n=200) and women (n=112). The severity of HF, based on the New York Heart Association functional class, averaged I-III in 7 studies (n=199), and III-IVa in 3 studies (n=72), whereas 8 studies did not report New York Heart Association values (n=97). With regard to prevailing comorbidities, coronary artery disease, hypertension, and diabetes mellitus were reported along with standard oral HF medical therapy in the majority of studies. Moreover, individuals with anemia-as defined by Hb concentration<13.0 g/dL in men and <12.0 g/ dL in women-were included in 7 studies (n=127). Iron status was described in 6 studies (n=189). Intravascular assessment was primarily performed through radioactive isotopes 15 studies (n=337), whereas 3 studies used dye dilution methods (n=31). All studies reported intravascular volumes in patients with chronic HF. Figure 2 illustrates the comparison of mean RBCV, PV, and BV, as expressed in % of normal values, in studies comprising HF individuals without anemia (determined by [Hb] ) versus those including HF individuals with anemia. RBCV was below normal values (limits 67%-88%) in all studies including HF individuals with anemia, whereas only 2 of 10 studies in patients with nonanemic HF presented lower than normal RBCV (90% and 96%). PV was augmented in all studies including HF individuals with anemia (123%-169%) and in 9 of 10 studies in patients with nonanemic HF (115%-138%). BV was predominantly elevated in studies including HF individuals with anemia (100%-133%) and studies in patients with nonanemic HF (100%-130%). 
BVs According to Anemia Status
Association Analyses Using Mean Study Values
Discussion Findings
In this systematic review, we examined summarized data from 18 studies, comprising a total of 368 patients with chronic HF with or without anemia as determined by [Hb] . The key finding of the present review is that true anemia, that is reduced RBCV, is present in all studies including individuals with HF and anemia, whereas normal RBCV predominates in studies involving patients with nonanemic HF. Augmented PV and BV are manifest in the vast majority of studies. In addition, main clinical variables, such as age, sex (% of females), LVEF, and BMI, have an inverse linear association with RBCV throughout HF phenotypes.
Nearly 4 in 10 individuals with HF present with anemia, being one of the most common comorbidities in HF. 7 For Data are n, prevalence (%), and mean or mean±SD. Three articles presented separate study groups that were distinguished by A, B, and C. 10, 16, 25 AB indicates α-blockers; ACEi, angiotensin-converting enzyme inhibitors; ACG, anticoagulants; ARB, angiotensin II-receptor blockers; ASA, acetylsalicylic acid; BB, β-blockers; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blockers; COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufficiency; DGT, digitalis; DIU, diuretics; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; [Hb] , hemoglobin concentration; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; Loop DIU, loop diuretics; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; NA, data not available; NTR, nitrates; RBCs, red blood cells; STN, statins; and THZ, thiazides. pragmatic reasons, [Hb] is widely used as a main diagnostic marker. However, anemia is strictly defined by a reduced number of circulating red blood cells or total RBCV, which may be dissociated from [Hb] in patients with HF due to fluid retention and associated increases in PV, that is, hemodilution. 8 However, preserved [Hb] and low PV, plausibly attributable to long-term or aggressive therapy targeting fluid overload, could mask true anemia in HF in the absence of thorough follow-up of clinical signs and hematologic parameters. 1, 14, 15 Yet, RBCV status in patients with HF remains unresolved, despite the large body of literature on intravascular volumes accumulated since the first half of the 20th century in this population.
3,5,9,10,15-26 A fraction , and blood volume (C) in patients with heart failure grouped according to anemia status. In each group, studies are ordered from left to right according to sample size.
3,9,10,15-26 True Anemia in Heart Failure of these studies, however, did not take into account the nonlinear influence of body size on intravascular volumes, thus compounding their inherent variability in the setting of HF. To our knowledge, the present investigation is the first systematic review aiming to delineate RBCV status in patients with HF.
To this end, we were attentive toward articles directly reporting or allowing the calculation of standardized intravascular volumes conforming to established International Council for Standardization in Hematology norms (19 studies, n=400).
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Our results indicate that the presence or absence of true anemia concurs with anemia determined by [Hb] cut-off levels ( Figure 2A ). In particular, mean RBCV ranged from 67% to 88% of normal reference values in all studies including HF individuals with anemia, while all studies comprising patients with nonanemic HF presented ≥90% of normal RBCV. These findings denote that true anemia is not a condition generally concealed by fluid retention and hemodilution in HF, although PV and BV are indeed commonly increased in these patients. Yet, exceptional cases in that [Hb] and RBCV can be dissociated, particularly when PV is decreased, deserve specific investigation. 14, 15 Taken together, the clinical significance of [Hb] in HF is reinforced by virtue of its correspondence with RBCV, thus partially curtailing the incertitude regarding the identification of true anemia in this population.
Despite the parallelism between [Hb] and RBCV, the question arises as to whether both variables are (linearly) associated with a similar set of prognostic factors. In this respect, clinical variables such as age, female sex, and history of kidney disease or hypertension were independently related to anemia, according to [Hb] levels, in a cohort of 12 065 patients with HF. 32 In this study, older age showed a negative linear relationship with RBCV. Specifically, RBCV declines ≈1% point from normal values for every 1 year increase in age. The relationship of older age with anemia has been primarily attributed to age-related impaired renal endocrine function, reduced androgen levels, and chronic low-grade inflammation, 33, 34 all potentially affecting erythropoiesis. In addition, female sex was also inversely associated with RBCV, decreasing half a percentage point per 1 U increase in % females. This association may be, at least in part, independent of the reduced intravascular volumes characteristic of females, since their calculation was adjusted for sex. 24, 27 Although the predominance of severe anemia in females with HF has been consistently described, 35, 36 underlying mechanisms have yet to be elucidated. While speculative, a contributing factor could be related to the higher prevalence of kidney disease in females with advancing age compared with males. 37 Additionally or alternatively, iron deficiency in females with HF could limit normal erythropoiesis, 38 in line with the present association between RBCV and ferritin derived from a minority subset of studies. In this regard, intravenous iron therapy has been recently related to lower cardiovascular mortality and improved functional exercise capacity in iron-deficient patients with HF. 39 Furthermore, we detected a negative relationship between LVEF and RBCV, which implies a distinct pathophysiology of anemia in HFrEF versus HFpEF patients, as discussed below.
Estimates of the prevalence of anemia (low [Hb]) reach 43% or higher in patients with HFpEF 40, 41 and are augmented compared with individuals with HFrEF. 16, 40 True anemia also seems to be more common in anemic patients with HFpEF than those with HFrEF, with respective prevalences of 90% and 60%. 16 The herein observation that RBCV is a linear function of LVEF across HF phenotypes agrees with previous evidence and suggests a potential central role of true anemia in the pathogenesis of HFpEF. In this respect, HFpEF is typically associated with hypertension, 42 which has been linked to anemia, as aforementioned. 32 Of note, hypertension in patients with HFpEF is commonly accompanied by the stiffening of central elastic arteries. 43 Arterial stiffness (AS) is a fundamental hallmark of sedentary aging, which is inexorably associated with a linear increase in AS, notably if concurring with increased adiposity. 44 Likewise, HFpEF is considered a disease of old age presenting with a high prevalence of obesity 45 -as a matter of fact, BMI was negatively associated with RBCV in regression analyses. Importantly, central AS is also negatively associated with RBCV. 46 Potential mechanisms explaining this relationship include AS-induced reduction of baroreflex sensitivity leading to impaired release of BV-regulating hormones directly stimulating erythropoiesis 47 and reduced renal perfusion. 48 Alternatively, increased AS and reduced RBCV could be caused by a common underlying process, for example, an age-related increase in circulating (adipose tissue derived) proinflammatory cytokines, 33 altering intrinsic arterial wall properties and proliferation/differentiation of erythroid progenitor cells. 43, 49 In addition, carotid AS is directly associated with a primary chronic symptom in HFpEF, severe exercise intolerance, as determined by the assessment of maximal oxygen consumption (VO 2max ). 43 Low VO 2max could be the consequence of diminished capacity to deliver oxygen essentially due to RBCV deficit. 50 Collectively considered, true anemia may be a dominant substrate in the pathophysiology of HFpEF primarily attributed to age-related impaired hemodynamic and hematologic regulation.
Limitations
There are some limitations to our analyses that require comment. First, available individual patient data were sparse and analyses were performed on mean variables of relatively small studies. Second, none of the included studies presented mean LVEF between 40% and 50%, which hinders any general conclusion on intravascular volume status about HF with midrange LVEF. Third, although the majority of studies used radioactive labeling techniques, 10, [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] 3 studies (n=31) used dye dilution for intravascular assessment, which could overestimate RBCV. 3, 15, 21 Nevertheless, the exclusion of these 3 studies did not materially affect the conclusions of this review.
Conclusions
The current systematic review indicates that true (nonhemodilutional) anemia is common to patients with chronic HF characterized by anemia, as routinely determined by [Hb] , but mainly absent in those presenting with normal [Hb] . Moreover, regression analyses suggest that the degree of true anemia, represented by RBCV status, is a linear function of older age, female sex, LVEF, and BMI in individuals with HF. These findings may contribute to clarify the complex management of intravascular volume regulation in patients with HF and facilitate early identification of patients with HF at risk for true anemia.
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